{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T07:31:06Z","timestamp":1787729466632,"version":"build-2784847793"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"9","funder":[{"name":"Intramural Research Program at the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institutes of Health"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the time-dependent effects of tocilizumab on vascular inflammation as measured by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in GCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with GCA treated with tocilizumab were selected from a prospective, observational cohort. Patients underwent FDG-PET at the baseline visit prior to initiation of tocilizumab and at subsequent follow-up visits performed at 6-month intervals. All imaging findings were interpreted blinded to clinical data. The PET vascular activity score (PETVAS) was used to quantify arterial FDG uptake. Wilcoxon signed rank test was used to compare change in PETVAS between visits. Linear regression was used to determine change in PETVAS over multiple timepoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five patients with GCA were included. All patients had physician-determined active vasculitis at the baseline visit by clinical assessment and FDG-PET interpretation. PETVAS was significantly reduced in association with tocilizumab treatment from the baseline to the most recent follow-up visit [24.0 (IQR 22.3\u201327.0) vs 18.5 (IQR 15.3\u201323.8); P\u00a0&amp;lt;0.01]. A significant reduction in PETVAS was observed over a two-year treatment period (P\u00a0&amp;lt;0.01 for linear trend), with a similar degree of improvement in both the first and second years of treatment. Repeat FDG-PET scans after tocilizumab discontinuation showed worsening PET activity in five out of six patients, with two patients subsequently experiencing clinical relapse.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Treatment of patients with GCA with tocilizumab was associated with both clinical improvement and reduction of vascular inflammation as measured by serial FDG-PET. Future clinical trials in GCA should study direct treatment effect on vascular inflammation as an outcome measure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa894","type":"journal-article","created":{"date-parts":[[2020,12,12]],"date-time":"2020-12-12T01:22:55Z","timestamp":1607736175000},"page":"4384-4389","source":"Crossref","is-referenced-by-count":63,"title":["Use of 18F-fluorodeoxyglucose positron emission tomography to monitor tocilizumab effect on vascular inflammation in giant cell arteritis"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0101-1580","authenticated-orcid":false,"given":"Kaitlin A.","family":"Quinn","sequence":"first","affiliation":[{"name":"Systemic Autoimmunity Branch, National Institutes of Health, NIAMS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Dashora","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, National Institutes of Health, NIAMS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Novakovich","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, National Institutes of Health, NIAMS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Ahlman","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Grayson","sequence":"additional","affiliation":[{"name":"Systemic Autoimmunity Branch, National Institutes of Health, NIAMS"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"2021120106181080500_keaa894-B1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/annrheumdis-2019-216145","article-title":"Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis","volume":"79","author":"Michailidou","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2021120106181080500_keaa894-B2","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.3899\/jrheum.141347","article-title":"Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study","volume":"42","author":"Kermani","year":"2015","journal-title":"J Rheumatol"},{"key":"2021120106181080500_keaa894-B3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"key":"2021120106181080500_keaa894-B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2021120106181080500_keaa894-B5","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(16)00560-2","article-title":"Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Villiger","year":"2016","journal-title":"Lancet"},{"key":"2021120106181080500_keaa894-B6","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1007\/s00259-018-3973-8","article-title":"FDG-PET\/CT(A) imaging in large vessel vasculitis and polymyalgia rheumatica: joint procedural recommendation of the EANM, SNMMI, and the PET Interest Group (PIG), and endorsed by the ASNC","volume":"45","author":"Slart","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2021120106181080500_keaa894-B7","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3899\/jrheum.181222","article-title":"Effect of treatment on imaging, clinical, and serologic assessments of disease activity in large-vessel vasculitis","volume":"47","author":"Banerjee","year":"2020","journal-title":"J Rheumatol"},{"key":"2021120106181080500_keaa894-B8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0003319717753223","article-title":"Tocilizumab in giant cell arteritis: a real-life retrospective study","volume":"69","author":"Vitiello","year":"2018","journal-title":"Angiology"},{"key":"2021120106181080500_keaa894-B9","doi-asserted-by":"crossref","first-page":"rkaa017","DOI":"10.1093\/rap\/rkaa017","article-title":"Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients","volume":"4","author":"Regola","year":"2020","journal-title":"Rheumatol Adv Pract"},{"key":"2021120106181080500_keaa894-B10","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2021120106181080500_keaa894-B11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/art.40044","article-title":"A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis","volume":"69","author":"Langford","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021120106181080500_keaa894-B12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2019.07.008","article-title":"Imaging acquisition technique influences interpretation of positron emission tomography vascular activity in large-vessel vasculitis","volume":"50","author":"Quinn","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2021120106181080500_keaa894-B13","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/annrheumdis-2018-213102","article-title":"Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis","volume":"77","author":"Quinn","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2021120106181080500_keaa894-B14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/art.40379","article-title":"18F-Fluorodeoxyglucose-positron emission tomography as an imaging biomarker in a prospective, longitudinal cohort of patients with large vessel vasculitis","volume":"70","author":"Grayson","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021120106181080500_keaa894-B15","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/rheumatology\/key015","article-title":"Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis","volume":"57","author":"Reichenbach","year":"2018","journal-title":"Rheumatology"},{"key":"2021120106181080500_keaa894-B16","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology"},{"key":"2021120106181080500_keaa894-B17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/art.21699","article-title":"Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients","volume":"55","author":"Blockmans","year":"2006","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaa894\/35199475\/keaa894.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4384\/41323924\/keaa894.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/9\/4384\/41323924\/keaa894.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:29:26Z","timestamp":1638332966000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/9\/4384\/6053807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":17,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,1,19]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa894","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,9,1]]},"published":{"date-parts":[[2021,1,19]]}}}